DDInter1112 DDInter1658
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Magaldrate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Magaldrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Magaldrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Magaldrate {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Magaldrate {u} may lead to a major life threatening interaction when taken with {v} Raltegravir
Magaldrate may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Magaldrate may lead to a major life threatening interaction when taken with Erdafitinib
Magaldrate may lead to a major life threatening interaction when taken with Raltegravir